Skip to main content
TTrialFinder
TrialFinder is for informational purposes only and does not provide medical advice. Always talk to your doctor.

Esophageal Cancer Clinical Trials

109 recruiting trials for Esophageal Cancer. Eligibility criteria explained in plain English.

Important: This information is not medical advice. Talk to your doctor about whether a clinical trial is right for you.
109
Total Trials
109
Recruiting Now
7
Phase 3 Trials
10
Sponsors

Recruiting Trials

Clinical trial data sourced from the ClinicalTrials.gov registry, maintained by the National Library of Medicine. Always consult your doctor before considering any clinical trial.

RECRUITINGPhase 1NCT06238479

A Study of LY4101174 in Participants With Recurrent, Advanced or Metastatic Solid Tumors

The purpose of this study is to find out whether the study drug, LY4101174, is safe, tolerable and effective in participants with select advanced or metastatic solid tumors. The...

Sponsor: Eli Lilly and CompanyEnrolling: 49020 locations
RECRUITINGNCT06019455

The Level of Patient Participation in Lung and Esophageal Cancer Patients Treated With Definitive Radiochemotherapy.

This study aims to assess the level of participation of thoracic cancer patients undergoing definitive radiotherapy and chemotherapy ± immunotherapy in their medical processes and...

Sponsor: Sun Yat-sen UniversityEnrolling: 5001 location
RECRUITINGPhase 1 / Phase 2NCT06047379

Safety and Efficacy of NEO212 in Patients With Astrocytoma IDH-mutant, Glioblastoma IDH-wildtype or Brain Metastasis

This multi-site, Phase 1/2 clinical trial is an open-label study to identify the safety, pharmacokinetics, and efficacy of a repeated dose regimen of NEO212 alone for the...

Sponsor: Neonc Technologies, Inc.Enrolling: 1346 locations
RECRUITINGNCT05366881

cfDNA Assay Prospective Observational Validation for Early Cancer Detection and Minimal Residual Disease

This is an observational case-control study to train and validate a genome-wide methylome enrichment platform to detect multiple cancer types and to differentiate amongst cancer...

Sponsor: Adela, IncEnrolling: 700017 locations
RECRUITINGPhase 1 / Phase 2NCT03556228

VMD-928 Monotherapy and in Combination With Pembrolizumab to Treat TrkA Overexpression Driven Solid Tumors or Lymphoma

This is a multicenter, open-label, Phase 1/2 study of orally administered VMD-928 monotherapy and in combination with pembrolizumab in adult subjects with advanced solid tumors or...

Sponsor: VM Oncology, LLCEnrolling: 24215 locations
RECRUITINGNCT06822413

Raman Spectroscopy-Based Deep Learning Model for Early Pan-Cancer Early Diagnosis

The goal of this observational study is to explore whether a Raman-based, deep learning-assisted approach can be used to develop an effective method for early pan-cancer...

Sponsor: Second Affiliated Hospital, School of Medicine, Zhejiang UniversityEnrolling: 6004 locations
RECRUITINGPhase 1NCT06500052

A Study of BL-M17D1 in Patients With Locally Advanced or Metastatic HER2 Positive/Lower Expression Gastrointestinal...

This study is an open, multicenter, dose-escalation and expansion-enrollment nonrandomized phase I clinical study to evaluate the safety, tolerability, pharmacokinetic...

Sponsor: Sichuan Baili Pharmaceutical Co., Ltd.Enrolling: 201 location
RECRUITINGPhase 1NCT03740256

Binary Oncolytic Adenovirus in Combination With HER2-Specific Autologous CAR VST, Advanced HER2 Positive Solid Tumors

This study is a first in human Phase 1 study that involves patients with a type of cancer called HER2 (Human Epidermal Growth Factor Receptor 2) positive cancer. This study asks...

Sponsor: Baylor College of MedicineEnrolling: 451 location
RECRUITINGPhase 1 / Phase 2NCT07410676

EBNK-001 Allogeneic NK Cells With Low-Dose IL-15 ± Pembrolizumab in Advanced Solid Tumors

This Phase 1/2 study evaluates the safety, tolerability, and preliminary anti-tumor activity of EBNK-001 (allogeneic NK cells) given after lymphodepleting...

Sponsor: Essen BiotechEnrolling: 831 location
RECRUITINGNCT04986293

CPAP or BiPAP for Motion Mitigation During Radiotherapy

When using highly conformal radiotherapy techniques, such as proton therapy, a controlled breathing pattern and a minimal breathing amplitude could greatly benefit the treatment...

Sponsor: University Medical Center GroningenEnrolling: 311 location
RECRUITINGPhase 1NCT07390838

A Study of SH009 Injection in Patients With Advanced Solid Tumors.

Evaluate the efficacy and safety of SH009 injection therapy for patients with advanced solid tumors

Sponsor: Nanjing Sanhome Pharmaceutical, Co., Ltd.Enrolling: 1501 location
RECRUITINGNCT06116019

Online Adaptive Radiotherapy Using a Novel Linear Accelerator (ETHOS)

The study focuses on the scientific and clinical evaluation of online adaptive radiotherapy (ART) using the Varian/SHS ETHOS treatment system. In this study, radiation treatment...

Sponsor: Charite University, Berlin, GermanyEnrolling: 6491 location
RECRUITINGPhase 1NCT07090499

A Study to Learn About the Study Medicine Called PF-08046876 in People With Advanced Solid Tumors

The purpose of the study is to explore the safety and effects of the study drug (PF-08046876) in people diagnosed with advanced cancer of the bladder, lung, head and neck,...

Sponsor: PfizerEnrolling: 31020 locations
RECRUITINGNCT02012699

Integrated Cancer Repository for Cancer Research

The iCaRe2 is a multi-institutional resource created and maintained by the Fred \& Pamela Buffett Cancer Center to collect and manage standardized, multi-dimensional, longitudinal...

Sponsor: University of NebraskaEnrolling: 99999920 locations
RECRUITINGPhase 1 / Phase 2NCT06239194

Dose Escalation and Dose Expansion Study of MDX2001 in Patients With Advanced Solid Tumors

This study is designed to characterize the safety, tolerability, and anti-tumor activity of MDX2001 in patients with advanced solid tumors.

Sponsor: ModeX Therapeutics, An OPKO Health CompanyEnrolling: 1156 locations
RECRUITINGNCT01048281

Clinical & Pathological Studies of Upper Gastrointestinal Carcinoma

Our research of the biology of upper gastrointestinal cancers involves the study of tissue samples and cells from biopsies of persons with gastric or esophageal cancer or blood...

Sponsor: Stanford UniversityEnrolling: 1001 location
RECRUITINGPhase 2NCT06123338

A Study of Pembrolizumab With Trastuzumab and Chemotherapy in People With Esophagogastric Cancer

The purpose of this study to find out whether adding trastuzumab and pembrolizumab to standard chemotherapy is an effective treatment for resectable HER2+ esophagogastric cancer.

Sponsor: Memorial Sloan Kettering Cancer CenterEnrolling: 4910 locations
RECRUITINGNCT07175155

Combination of COMBO Endoscopy Oropharyngeal Airway and HFNC Oxygenation in Sedated Gastrointestinal Endoscopy for...

Hypoxaemia during sedated gastrointestinal endoscopy exceeds 40 % in morbidly obese (BMI ≥ 35 kg m-²) patients. High-flow nasal cannula alone often fails because of persistent...

Sponsor: Zhejiang UniversityEnrolling: 4105 locations
RECRUITINGPhase 2NCT06398405

A Phase II Clinical Study of Epigallocatechin-3-gallate in Patients With Esophageal Squamous Cancer

The investigators conduct this phase II study to evaluate safety and effectiveness of EGCG in patients with dysphagia. Swallowing-related dysphagia and pain scores were recorded...

Sponsor: Shandong Cancer Hospital and InstituteEnrolling: 721 location
RECRUITINGPhase 3NCT05547529

The Efficacy of Neoadjuvant Chemoradiotherapy in Comparison With Neoadjuvant Chemotherapy in Patients With Resectable...

The purpose of this study is to evaluate the safety, feasibility and outcomes of neoadjuvant chemotherapy followed by esophagectomy versus neoadjuvant chemoradiotherapy followed...

Sponsor: Blokhin's Russian Cancer Research CenterEnrolling: 1561 location
RECRUITINGPhase 2NCT06962137

Phase II RAINSPOT: Zolbetuximab-Paclitaxel-Ramucirumab for CLDN18.2 Positive Gastro-esophageal Cancer

This study examines whether adding the drug Zolbetuximab to an existing treatment (Paclitaxel and Ramucirumab) can improve patients' survival. The goal is to see if this...

Sponsor: Universitaire Ziekenhuizen KU LeuvenEnrolling: 1006 locations
RECRUITINGPhase 1 / Phase 2NCT04592211

Pembrolizumab, Olaparib, Recurrent/Advanced Gastric and Gastro-esophageal Junction(GEJ) Cancer

Pembrolizumab is a potent humanized immunoglobulin G4 (IgG4) monoclonal antibody (mAb) with high specificity of binding to the programmed cell death 1 (PD 1) receptor, thus...

Sponsor: Yonsei UniversityEnrolling: 711 location
RECRUITINGNCT05753748

Surveillance vs. Endoscopic Therapy for Barrett's Esophagus With Low-grade Dysplasia

The purpose of this study is to learn the best approach to treating patients with known or suspected Barrett's esophagus by comparing endoscopic surveillance to endoscopic...

Sponsor: University of Colorado, DenverEnrolling: 68020 locations
RECRUITINGPhase 2NCT05252078

Anlotinib Hydrochloride Capsules Combined With TQB2450 Injection in Esophageal Squamous Cell Carcinoma Patients

This is an Open, Single Arm, Exploratory and Phase II Clinical Trial of Anlotinib Hydrochloride Capsules Combined With TQB2450 Injection in Esophageal Squamous Cell Carcinoma...

Sponsor: Jiangxi Provincial Cancer HospitalEnrolling: 301 location
RECRUITINGPhase 1 / Phase 2NCT06975410

Clinical Trial of YH32364 in Patients With Locally Advanced or Metastatic EGFR Overexpressing Solid Tumors

This is a study for people with locally advanced or metastatic cancer for whom previous treatment was not successful. Adults aged 18 and over with advanced cancer with Epidermal...

Sponsor: Yuhan CorporationEnrolling: 804 locations
RECRUITINGNCT07354295

Integrating Multimodal AI to Predict Treatment Response and Refine Risk Stratification in Esophageal Cancer...

This AI-driven model leverages multimodal data-such as radiomics, pathomics, genomics, and broader multi-omics profiles-to capture complementary aspects of tumor biology and...

Sponsor: Shu PengEnrolling: 15001 location
RECRUITINGNCT06136845

The Correlation Between Microbiome of Esophageal Cancer Patients and Post Esophagectomy Anastomotic Leaks

Esophageal cancer continues to be one of the most challenging topics and the subjects of numerous studies. Surgery is the mainstay for curative treatment and the need to improve...

Sponsor: Rambam Health Care CampusEnrolling: 3001 location
RECRUITINGNCT05818072

The Prevalence, Risk Factors and Optimal Biopsy Protocol of BE

Detections of goblet cells and dysplasia are crucial for diagnosis and determining the surveillance program of Barrett's esophagus (BE). However, the optimal biopsy numbers and...

Sponsor: E-DA HospitalEnrolling: 1651 location
RECRUITINGPhase 2 / Phase 3NCT06138028

Sintilimab and Chemotherapy Sequential Radiotherapy in Advanced Esophageal Cancer

This is an investigator-initiated, single-arm, exploratory clinical study.The study population consisted of treatment naive advanced esophageal squamous cell carcinoma patients....

Sponsor: Qingdao Central HospitalEnrolling: 902 locations
RECRUITINGPhase 1 / Phase 2NCT05937438

Postoperative Radiotherapy Followed by Immunotherapy for Locally Advanced Esophageal Carcinoma

Esophageal squamous cell carcinoma is a common malignancy in China. Although neoadjuvant chemoradiotherapy followed by esophagectomy remains a standard modality for locally...

Sponsor: Anhui Provincial HospitalEnrolling: 701 location
RECRUITINGPhase 1NCT05969041

Study of MT-302 in Adults With Advanced or Metastatic Epithelial Tumors

MYE Symphony is a multicenter, open-label, Phase 1 first-in-human study to assess the safety, tolerability, and define the RP2D of MT-302 in participants with advanced epithelial...

Sponsor: Myeloid TherapeuticsEnrolling: 486 locations
RECRUITINGPhase 2NCT07266493

Efficacy and Safety of Neoadjuvant Envafolimab Combined With Albumin-bound Paclitaxel and Carboplatin for Resectable...

This single center, prospective, single arm clinical study aims to evaluate the clinical efficacy and safety of Envafolimab combined with albumin bound paclitaxel and carboplatin...

Sponsor: Shanghai Zhongshan HospitalEnrolling: 261 location
RECRUITINGPhase 2NCT06912074

Hypofractionated vs. Conventional Chemoradiotherapy After Induction Chemo-immunotherapy for Unresectable Esophageal...

This is a prospective, open-label, randomized phase II clinical trial designed to compare the efficacy and toxicity of hypofractionated concurrent chemoradiotherapy versus...

Sponsor: Sun Yat-sen UniversityEnrolling: 1341 location
RECRUITINGNCT05028725

Novel Strategy for Early Detection of Esophageal Squamous Cell Carcinoma

In the current protocol, we propose a study to evaluate a novel, combined esophageal sponge-methylation biomarker strategy for the early detection of esophageal squamous cell...

Sponsor: University of California, San FranciscoEnrolling: 2892 locations
RECRUITINGPhase 3NCT06339060

An Organ Preservation Strategies After Chemoradiotherapy Combined With Immunotherapy for Esophageal Cancer (PALACE3).

Patients with locally advanced esophageal squamous cell carcinoma will randomly assigned to receive neoadjuvant chemo-radiotherapy combined with immunotherapy post organ...

Sponsor: Ruijin HospitalEnrolling: 3561 location
RECRUITINGNCT07251114

AI-assisted Endoscopic Ultrasound Grading of Early Esophageal Cancer Invasion Depth: A Multicenter, Prospective,...

This study mainly uses an artificial intelligence system to assist in the classification of the depth of invasion of early esophageal squamous cell carcinoma under ultrasound...

Sponsor: Fujian Provincial HospitalEnrolling: 2005 locations
RECRUITINGPhase 2NCT07457528

Efficacy and Safety of Neo-CRT Plus Serplulimab, Nimotuzumab in Patients With Locally Advanced Resectable ESCC

This trial is conducted in patients with resectable locally advanced esophageal squamous cell carcinoma. The investigators plan to enroll 46 patients with resectable locally...

Sponsor: Tianjin Medical University Cancer Institute and HospitalEnrolling: 461 location
RECRUITINGPhase 2NCT06586242

Efficacy and Safety of Penpulimab Combined With Anlotinib and Chemotherapy

This study is a two arm, randomized, prospective, multicenter study on the perioperative treatment of locally advanced resectable esophageal cancer with penpulimab combined with...

Sponsor: Xijing HospitalEnrolling: 1941 location
RECRUITINGNCT04867590

A Study Comparing the Effectiveness of EndoRotor Versus Radiofrequency in Treating Barrett's Esophagus

Barrett Esophagus is a common pathology, with an estimated prevalence of 1.6% at risk of progression to precancerous mucosa (low to high grade dysplasia). The incidence of...

Sponsor: University Hospital, AngersEnrolling: 14012 locations
RECRUITINGNCT06490003

Predicting Postoperative Chemotherapy Efficacy in Patients With Esophageal Squamous Cell Carcinoma

Esophageal cancer remains a disease with a poor prognosis. Chemotherapy is an important part of its treatment, but there are cases in which chemotherapy is ineffective. The...

Sponsor: City of Hope Medical CenterEnrolling: 1501 location
RECRUITINGPhase 2NCT04114136

Anti-PD-1 mAb Plus Metabolic Modulator in Solid Tumor Malignancies

Patients with histologically or cytologically confirmed advanced melanoma, renal cell carcinoma, NSCLC, HCC (Child Pugh Class A only), MSI-High solid tumors, Urothelial Cancer, GE...

Sponsor: Dan ZandbergEnrolling: 721 location
RECRUITINGNCT06192771

Feasibility of Early Swallowing and Speech Intervention for Head and Neck Cancer Patients Treated SURGically

Oral cavity cancer (OCC) is one of the most common cancers worldwide, with tongue cancer being one of the most common subtypes. Patients with oral cancers can experience painful...

Sponsor: University Health Network, TorontoEnrolling: 401 location
RECRUITINGPhase 1 / Phase 2NCT06531434

Establishing Best Treatment Strategy for T4 Esophageal Cancer

The goal of this clinical trial is to investigate the safety and efficacy of a new treatment approach for T4-stage esophageal cancer, which involves chemoradiotherapy after...

Sponsor: National Cheng-Kung University HospitalEnrolling: 221 location
RECRUITINGPhase 3NCT05495152

Adjuvant Sintilimab for Locally Advanced Esophageal Squamous Cell Carcinoma

No adjuvant treatment has been established for patients who remain at high risk for recurrence after neoadjuvant chemotherapy plus surgery and incidental pathologic lymph node...

Sponsor: Henan Cancer HospitalEnrolling: 2192 locations
RECRUITINGPhase 2NCT06122493

Optimization of Treatment Strategy for Unresectable cN3 Esophageal Squamous Cell Carcinoma

This study aims to investigate a comprehensive therapeutic approach for patients with unresectable esophageal squamous cell carcinoma, clinically staged as Tany, N3, M0, and who...

Sponsor: Ruijin HospitalEnrolling: 481 location
RECRUITINGNCT04221893

Radiation Therapy for the Treatment of Metastatic Gastrointestinal Cancers

This phase II trial studies how well radiation therapy works for the treatment of gastrointestinal cancer that are spreading to other places in the body (metastatic). Radiation...

Sponsor: University of California, San FranciscoEnrolling: 282 locations
RECRUITINGNCT06532734

Barrett's Esophagitis in Anorexia Nervosa Binge/Purge Subtype

To better define the presence of Barrett's esophagus (BE) via non-endoscopic testing in an eating disorder cohort with purging (vomiting/rumination) behaviors

Sponsor: Denver Health and Hospital AuthorityEnrolling: 253 locations
RECRUITINGPhase 2NCT06421376

Induction Chemoimmunotherapy Combined With Chemoradiotherapy in Esophageal Cancer

Although unprecedented advances have been made in the field of esophageal cancer in recent decades, the prognosis for patients with locally advanced esophageal squamous cell...

Sponsor: Cancer Institute and Hospital, Chinese Academy of Medical SciencesEnrolling: 603 locations
RECRUITINGPhase 2NCT07290010

The Efficacy and Safety of Iparomlimab and Tuvonralimab Injection Combined With Chemotherapy as the First-line...

This study is a single-arm clinical trial to evaluate the efficacy and safety of Iparomlimab and Tuvonralimab combined with chemotherapy in the first-line treatment of patients...

Sponsor: Hebei Medical University Fourth HospitalEnrolling: 251 location
RECRUITINGPhase 2NCT06869213

A Single-arm, Open, Single-center Exploratory Study of Adebrelimab (SHR-1316) in Combination With Chemotherapy for the...

This study is a prospective, observational clinical study. In this study, 30 patients with resectable locally advanced esophageal squamous carcinoma will be prospectively enrolled...

Sponsor: Peking University Cancer Hospital & InstituteEnrolling: 301 location

Showing 50 of 109 trials.Search all Esophageal Cancer trials

Frequently Asked Questions

There are currently 109 clinical trials for Esophageal Cancer, with 109 actively recruiting participants. These include trials across all phases from early-stage Phase 1 to late-stage Phase 3.

To join a clinical trial for Esophageal Cancer, review the eligibility criteria on the trial detail pages, then talk to your doctor about whether a trial is right for you. Your doctor can help you evaluate the potential benefits and risks.

Phase 3 trials are large-scale studies that test whether a treatment is effective and monitor side effects. There are 7 Phase 3 trials for Esophageal Cancer, representing treatments closest to potential FDA approval.

Clinical trials follow strict safety protocols overseen by Institutional Review Boards (IRBs) and the FDA. Participants are monitored closely and can withdraw at any time. Always discuss risks and benefits with your healthcare provider before enrolling.

Sources: ClinicalTrials.gov, FDA
Last updated:

Trial data sourced from the ClinicalTrials.gov API. This site does not provide medical advice — always talk to your doctor about clinical trial participation.